Zenas BioPharma Inc. (ZBIO)
NASDAQ: ZBIO
· Real-Time Price · USD
16.82
0.06 (0.36%)
At close: Aug 15, 2025, 3:59 PM
17.00
1.07%
After-hours: Aug 15, 2025, 05:40 PM EDT
Zenas BioPharma Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
Revenue | 15M | 15M | 5M | n/a | 50M | 50M | 50M | 50M | n/a | n/a | n/a |
Cost of Revenue | 104K | 127K | 137K | 20.52M | 20.51M | 20.48M | 20.44M | 26K | n/a | n/a | n/a |
Gross Profit | 14.95M | 14.93M | 4.9M | -20.52M | 29.51M | 29.55M | 29.58M | 50M | n/a | n/a | n/a |
Operating Income | -189.1M | -173.64M | -163.89M | -133.04M | -56.44M | -45.64M | -37.15M | -31.36M | -66.98M | -38.08M | -18.99M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -176.76M | -162.54M | -156.56M | -128.67M | -54.45M | -45.52M | -36.82M | -31.53M | -67.14M | -38.09M | -18.99M |
Net Income | -176.97M | -162.76M | -156.99M | -128.97M | -54.76M | -45.83M | -37.12M | -31.53M | -67.14M | -38.09M | -18.99M |
Selling & General & Admin | 43.47M | 37.23M | 29.75M | 22.64M | 20.21M | 18.31M | 17.11M | 15.98M | 10.95M | 6.96M | 3.22M |
Research & Development | 160.63M | 151.41M | 139.14M | 110.4M | 86.22M | 67.33M | 60.03M | 55.38M | 46.03M | 31.11M | 15.77M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | 10M | 10M | 10M | 10M | n/a | n/a |
Operating Expenses | 204.1M | 188.64M | 168.89M | 133.04M | 106.44M | 95.64M | 87.15M | 81.36M | 66.98M | 38.08M | 18.99M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 204.1M | 188.64M | 168.89M | 133.04M | 106.44M | 95.64M | 87.15M | 81.36M | 66.98M | 38.08M | 18.99M |
Income Tax Expense | 244K | 224K | 429K | 301K | 301K | 301K | 301K | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 41.87M | 41.8M | 41.79M | 41.78M | 38.32M | 38.32M | 38.32M | 41.78M | 38.32M | 38.32M | 38.32M |
Shares Outstanding (Diluted) | 41.87M | 41.8M | 41.79M | 41.78M | 38.32M | 38.32M | 38.32M | 41.78M | 38.32M | 38.32M | 38.32M |
EPS (Basic) | -4.23 | -3.97 | -3.9 | -3.28 | -2.15 | -1.92 | -1.69 | -1.55 | -1.76 | -1 | -0.5 |
EPS (Diluted) | -4.23 | -3.97 | -3.9 | -3.28 | -2.15 | -1.92 | -1.69 | -1.55 | -1.76 | -1 | -0.5 |
EBITDA | -185.46M | -169.96M | -163.75M | -132.91M | -56.31M | -35.52M | -27.03M | -21.25M | -56.9M | -38.02M | -18.96M |
EBIT | -182.59M | -170.09M | -163.89M | -133.04M | -56.44M | -35.64M | -27.15M | -21.36M | -56.98M | -38.08M | -18.99M |
Depreciation & Amortization | 104K | 127K | 137K | 134K | 124K | 118K | 113K | 108K | 82K | 53K | 25K |